Inhibition of Amyloid-β Aggregation in Alzheimer's Disease

Author(s): Qiuming Wang, Xiang Yu, Lingyan Li, Jie Zheng.

Journal Name: Current Pharmaceutical Design

Volume 20 , Issue 8 , 2014


The assembly of naturally occurring amyloid peptides into cytotoxic oligomeric and fibrillar aggregates is believed to be a major pathologic event in over 25 human diseases. Blocking of or interfering with the aggregation of amyloid peptides such as amyloid-β (Aβ) using small organic molecules, peptides and peptidomimetics, and nanoparticles that selectively bind or inhibit Aβ aggregates is a promising strategy for the development of novel pharmaceutical approaches and agents to treat Alzheimer's disease (AD). In a broad sense, considering many common features in structure, kinetics, and biological activity of amyloid peptides, potent inhibitors and associated inhibition strategies that are developed for targeting Aβ aggregation could also be generally applied to other amyloid-forming peptides in “protein-aggregation diseases”. Due to the complex nature of Aβ self-assembly process, increasing knowledge in high-resolution structures of Aβ oligomers, atomic-level Aβ-inhibitor binding information, and cost-effective high-throughput screening method will improve our fundamental understanding of amyloid formation and inhibition mechanisms, as well as practical design of pharmaceutical strategies and drugs to treat AD. This review summarizes major findings, recent advances, and future challenges for the development of new Aβ-aggregation inhibitors, mainly focusing on three major classes of Aβ inhibitors with associated inhibition mechanisms and practical examples.

Keywords: Amyloid-beta, Amyloid inhibitor, Amyloid toxicity, Protein aggregation, Alzheimer disease.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Page: [1223 - 1243]
Pages: 21
DOI: 10.2174/13816128113199990068
Price: $65

Article Metrics

PDF: 119